| Literature DB >> 26796202 |
Mahua Basu1, Kamlesh Mayana2, S Xavier1, S Balachandran3, Nibha Mishra4.
Abstract
Naturally, occurring compounds with MAO inhibitory property may provide promising lead molecules against neurodegenerative disorders. We report MAO inhibitory activity of a naturally occurring coumarin (validated chemical scaffold as MAO inhibitors), scopoletin. It selectively (and reversibly) inhibits human (Ki = 20.7 μM) and mouse (Ki = 22 μM) MAO-B, ∼3.5 times more selective towards MAO-B than MAO-A. Docking studies revealed its molecular recognition and explained the selectivity mechanism towards MAO isoforms. Scopoletin occupied the hydrophobic aromatic pockets showing favorable interactions for MAO-B; experimental Ki agreed with the predicted Ki. In vivo, scopoletin (80 mg/kg, i.p.) treatment significantly increases dopamine level and decreases its metabolite DOPAC in striatum. Overall, scopoletin is a partially selective MAO-B inhibitor that increases brain dopamine level.Entities:
Keywords: Docking; Dopamine; Monoamine oxidase; Scopoletin
Mesh:
Substances:
Year: 2016 PMID: 26796202 DOI: 10.1016/j.neuint.2016.01.001
Source DB: PubMed Journal: Neurochem Int ISSN: 0197-0186 Impact factor: 3.921